Antiviral fiber structure and its manufacturing method, and antiviral processed product
The integration of a quaternary ammonium halide with a molecular weight of 3000 or less into textile structures provides effective antiviral properties against viruses like the new coronavirus, addressing the inefficiencies of existing textile structures and ensuring rapid virus inactivation with low costs.
Patent Information
- Application Number
- JP2020211616
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2020-12-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-12-21
AI Technical Summary
Existing textile structures in household goods and medical supplies lack effective antiviral properties, making it difficult to efficiently kill viruses upon contact.
An antiviral fiber structure comprising a quaternary ammonium halide with a molecular weight of 3000 or less, applied at a specific basis weight and supported on the fiber surface, which can be integrated into nonwoven, woven, or knitted fabrics, without the need for special equipment or film-forming compounds.
The antiviral fiber structure exhibits rapid inactivation of target viruses, including the new coronavirus, with high safety for the human body and low manufacturing costs, demonstrating excellent antiviral properties even with short-term contact.
Smart Images

Figure 0007579543000001 
Figure 0007579543000002
Abstract
Description
[Technical field]
[0001] The present invention relates to an antiviral fiber structure that reliably exhibits antiviral properties even after short-term contact and is highly safe, as well as a method for producing the same and an antiviral treated product. [Background technology]
[0002] Human and livestock fatalities and economic losses are enormous due to viruses such as human influenza virus, avian influenza virus (same genus as human influenza virus), coronavirus, norovirus, Ebola hemorrhagic fever virus, and AIDS virus, as well as bacteria such as Salmonella and pathogenic E. coli. In addition, the WHO has pointed out the risk of a pandemic due to coronavirus and avian influenza virus.
[0003] In order to protect humans and livestock from the threat of such viruses, various antiviral drugs have been developed. Disinfectants containing sodium hypochlorite, iodophor, cationic surfactants, etc. have been used in the past to treat enveloped viruses (human influenza virus, avian influenza virus, etc.). Recently, it has been reported that a liquid spray containing a composite of polyalkylene biguanide hydrochloride (PHMB) and a quaternary ammonium salt compound is effective against non-enveloped viruses (such as norovirus) (see Patent Document 1).
[0004] Meanwhile, various studies are being conducted on methods for directly imparting antiviral properties to various household products, including clothing, medical supplies, industrial materials, and the like, rather than using antiviral compounds as disinfectants that are sprayed or applied to hands or hard surfaces to disinfect them. For example, a method has been reported in which textile products are treated with an antibacterial component, specific polycarboxylic acids, and a crosslinking agent (see Patent Document 2). [Prior art documents] [Patent documents]
[0005] [Patent Document 1] JP 2013-14551 A [Patent Document 2] JP 2003-105674 A Summary of the Invention [Problem to be solved by the invention]
[0006] However, while disinfectants such as sprays can efficiently kill viruses, when antiviral properties are imparted to fiber structures used in various household items including clothing, medical supplies, industrial materials, and the like, it is difficult to efficiently kill viruses, and there remains a challenge in providing an antiviral fiber structure that has a rapid effect.
[0007] The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an antiviral fiber structure which can be preferably used for applications such as clothing and medical supplies, and which is highly safe for the human body and has an immediate effect, as well as a method for producing the same, and an antiviral processed product. [Means for solving the problem]
[0008] In order to achieve the above object, the present invention provides the following [1] to
[15] . [1] An antiviral fiber structure having an antiviral compound (A) and a fiber structure, wherein the antiviral compound (A) is a quaternary ammonium halide having a molecular weight of 3000 or less, and the fiber structure has a basis weight of 120 g / m 2 The following is an antiviral fiber structure. [2] The antiviral fiber structure according to [1], comprising the antiviral compound (A) in an amount of 0.1 to 8 parts by weight per 100 parts by weight of the fiber structure. [3] The antiviral fiber structure according to [1] or [2], wherein the antiviral compound (A) is supported on at least the surface of the fiber structure. [4] The antiviral fiber structure according to any one of [1] to [3], wherein the quaternary ammonium halide of the antiviral compound (A) is a salt of an anion and a cation. [5] The antiviral fiber structure according to any one of [1] to [4], wherein the anion species constituting the quaternary ammonium halide of the antiviral compound (A) is at least one selected from the group consisting of iodide, bromide and chloride. [6] The antiviral fiber structure according to any one of [1] to [5], wherein the target virus is at least one selected from the group consisting of influenza virus, norovirus, and coronavirus. [7] The antiviral fiber structure according to any one of [1] to [6], wherein the fiber structure has fibers made of at least one selected from the group consisting of polyester resins, polyamide resins, acrylic resins, polyurethane resins, polyolefin resins, cellulose resins, acetate resins, cotton, hemp, wool, and silk. [8] The antiviral fiber structure according to any one of [1] to [7], wherein the fiber structure is a nonwoven fabric. [9] The antiviral fiber structure according to any one of [1] to [8], further comprising a fiber processing aid.
[10] The antiviral fiber structure according to [9], wherein the fiber processing aid is at least one selected from the group consisting of antistatic agents, flame retardants and softening agents.
[11] A method for producing an antiviral fiber structure according to any one of [1] to
[10] , comprising the steps of preparing a treatment liquid containing the antiviral compound (A) and contacting the fiber structure with the treatment liquid.
[12] The method for producing an antiviral fiber structure according to
[11] , further comprising a heat treatment step including a treatment at 40 to 230°C under normal pressure or pressure, after the step of contacting the fiber structure with the treatment liquid.
[13] An antiviral processed product obtained by processing the antiviral fiber structure described in any one of [1] to
[10] .
[14] The antiviral processed product according to
[13] , which is at least one selected from the group consisting of medical supplies, sanitary products, and cooking supplies.
[15] The virus-treated product according to
[13] or
[14] , wherein the anti-virus treated product is protective clothing.
[0009] In the present invention, the term "fibrous structure" refers to a textile product made of fibers or yarns made of fibers. Examples of the fiber structures include "woven fabrics" made of warp and weft threads that are perpendicular to each other, "knitted fabrics" made of continuous loops of unidirectional threads, and "nonwoven fabrics" made by bonding fibers by entangling, bonding, welding, or the like to form a sheet. The above-mentioned fibers include, for example, cotton, hemp, wool, silk and other natural fibers, and chemical fibers such as polyester, polyamide, acrylic, polyurethane, polyolefin, rayon, staple fiber, nylon, and vinylon.
[0010] That is, the present inventors have conducted extensive research to develop an antiviral fiber structure that is highly safe for the human body and is preferably used for clothing and interior decoration. As a result, they have found that a treatment solution is prepared by adding an antiviral compound (A) consisting of a quaternary ammonium halide having a molecular weight of a certain size or less, among quaternary ammonium salts conventionally known as antibacterial agents, in a dissolved or dispersed state in a solvent such as water, and that the treatment solution is brought into contact with a fiber structure having a specific basis weight, whereby the antiviral compound (A) is supported on the fiber structure and has an immediate effect. The inventors then discovered that the fiber structure carrying the antiviral compound (A) exhibits excellent antiviral properties against the SARS-CoV-2 virus (hereinafter sometimes referred to as the "novel coronavirus"), which has been wreaking havoc in recent years, and thus completed the present invention. Effect of the Invention
[0011] Thus, according to the antiviral fiber structure of the present invention, a specific antiviral compound (A) is used and the fiber structure has a specific basis weight, which is thought to facilitate migration of the target virus inside the fiber structure and increase the probability of contact with the antiviral compound (A) supported on the fiber structure. As a result, the target virus can be inactivated in a short period of time and, in particular, excellent antiviral properties can be exhibited against the new coronavirus. Furthermore, the production does not require the use of special equipment, and if there is equipment for contacting a fiber structure with a treatment solution containing the antiviral compound (A) (such as equipment for dyeing a fiber structure), the equipment can be used as is, thereby making it possible to keep production costs low. In addition, there is no need for a coating-forming compound (so-called binder resin) for supporting the antiviral compound (A), which is an advantage in that no extra material costs are incurred. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] Next, the embodiments for carrying out the present invention will be described in detail, but the present invention is not limited to these.
[0013] <Fiber structure> First, the fiber structure to which the present invention is intended to impart antiviral properties refers to a fiber product composed of fibers or yarns made of fibers, as described above, and examples of such a fiber include woven fabrics, knitted fabrics, nonwoven fabrics, braids, lace, nets, etc., and are preferably woven fabrics, knitted fabrics, and nonwoven fabrics, and more preferably nonwoven fabrics. That is, in nonwoven fabrics, fibers are generally randomly oriented, and therefore the fibers are unlikely to move or deform freely, and therefore there is a tendency that the supportability of the antiviral compound (A) is not impaired and superior antiviral properties can be maintained for a long period of time. In addition, when the fiber structure is a nonwoven fabric, it can be suitably used in disposable processed products, and is easy to use due to its excellent hygiene and storage properties.
[0014] The fibers used in the fiber structure may be chemical fibers or natural fibers, as described above. Examples of the chemical fibers include synthetic resins such as acrylic resins, polyester resins, polyamide resins, polyurethane resins, cellulose resins, and acetate resins, and mixtures of these fibers may also be used. Examples of the natural fibers include cotton, hemp, silk, and wool, and mixtures of these fibers may also be used. In addition, the chemical fibers and natural fibers may be mixed with other components (metals, inorganic substances, etc.).
[0015] Among them, the fiber structure is preferably one having fibers made of at least one selected from the group consisting of polyester resin, polyamide resin, acrylic resin, polyurethane resin, polyolefin resin, cellulose resin, acetate resin, cotton, hemp, wool, and silk, since it tends to provide both the supportability of the antiviral compound (A) on the fiber structure and the breathability and good touch of the fiber. Among these, it is more preferable that the fiber is made of at least one selected from the group consisting of polyester resin, polyurethane resin, polyolefin resin, cellulose resin, acetate resin, cotton, hemp, wool, and silk, and it is even more preferable that the fiber is made of at least one selected from the group consisting of polyester resin, polyolefin resin, cellulose resin, cotton, hemp, wool, and silk.
[0016] The weight of the fiber structure is 120 g / m 2 or less, preferably 10 to 100 g / m 2 The range is 20 to 80 g / m 2It is more preferable that the antiviral compound (A) is in the range. When the basis weight of the fiber structure is within the above range, the antiviral compound (A) can be supported on the fiber structure by simply contacting a fiber structure having a specific basis weight with a treatment liquid containing the antiviral compound (A) dissolved or dispersed in a solvent such as water. This further improves the contact probability between the virus and the antiviral compound (A), and in particular, there is a tendency that excellent antiviral properties against the new coronavirus can be exhibited even in a short contact period (for example, about 5 to 10 minutes). The basis weight of the fiber structure can be measured in accordance with "mass per unit area under standard conditions" specified in JIS L 1096 (2010) 8.3.2.
[0017] As described above, the present invention preferably uses a nonwoven fabric as the fiber structure. When a nonwoven fabric is used, the preferred basis weight is 10 to 80 g / m 2 The range is 15 to 70 g / m 2 More preferably, the range is 20 to 60 g / m 2 The range is more preferred.
[0018] When a woven fabric or knitted fabric is used as the fiber structure, the preferred basis weight is 50 to 120 g / m 2 The range is 60 to 110 g / m 2 The range of 70 to 100 g / m is more preferable. 2 The range is more preferred. In addition, when a woven fabric or a knitted fabric is used as the above-mentioned fiber structure, its basis weight (g / m 2 ) can also be calculated from the density of the woven or knitted fabric used in the fiber structure, the volume of the woven or knitted fabric, and the density of the fibers as follows: Here, d(m) below indicates the diameter of the fiber. Woven or knitted fabric weight (g / m 2 ) = Density of woven or knitted fabric x 2 (length x width) x volume of woven or knitted fabric x fiber density = Density of woven or knitted fabric (number of meshes / 2.54cm) x (100 / 2.54) x 2 x π x (d(m) / 2) 2 x 1m x fiber density (g / m 3 )
[0019] The diameter d (m) of the fiber can be calculated from the fineness of the fiber used in the woven or knitted fabric. That is, assuming that the cross section of the fiber is a perfect circle, the diameter of the fiber is d (cm), and the specific gravity of the fiber (g / cm 3 ) is p and the single fiber fineness of the fiber is Tex, the diameter d (cm) of 1 g of fiber in 1000 m can be expressed as follows using the single fiber fineness Tex of the fiber. π×(d(cm) / 2) 2 x100000 x p = Tex Therefore, it can be expressed as d(cm) = √{4×Tex / (π×100000×p)}.
[0020] The single fiber fineness of the fiber used in the fiber structure is preferably in the range of 0.1 to 400 dtex, more preferably in the range of 0.3 to 200 dtex, and even more preferably in the range of 0.4 to 100 dtex. When the fineness of the fiber structure is in the above range, the supportability (liquid retention) of the treatment liquid containing the antiviral compound (A) is improved, so that the probability of the target virus coming into contact with the antiviral compound (A) can be further increased. Therefore, even if the contact is for a short period of time (for example, about 5 to 10 minutes), excellent antiviral properties against the target virus can be exhibited.
[0021] In particular, when a nonwoven fabric is used as the fiber structure, the single fiber fineness is preferably in the range of 0.1 to 20 dtex, more preferably in the range of 0.5 to 10 dtex, and even more preferably in the range of 1 to 5 dtex. When a woven or knitted fabric is used as the fiber structure, the single fiber fineness of the fiber is preferably in the range of 30 to 400 dtex, more preferably in the range of 35 to 350 dtex, and further preferably in the range of 40 to 300 dtex.
[0022] The above-mentioned fiber structure has a specific surface area of 0.01 to 1 m 2 / g, and preferably 0.02 to 0.5 g / m 2 More preferably, the range is 0.03 to 0.1 m. 2 / g. When the specific surface area of the fiber structure is within the above range, the supportability (liquid retention) of the treatment liquid containing the antiviral compound (A) is improved, so that the probability of the target virus coming into contact with the antiviral compound (A) can be increased. Therefore, even if the contact is for a short period of time (for example, about 5 to 10 minutes), the excellent antiviral properties against the target virus can be exhibited.
[0023] The specific surface area of the above-mentioned fibrous structure can be calculated as follows. In the following formula, the side surface area of the fiber is approximately set to 0 for calculation. Specific surface area of the fiber structure (m 2 / g) = Sum of fiber surface areas / sum of weights (sum of fiber volumes x specific gravity) = (fiber yarn density [threads / m 2 ]×2π(d / 2)[m]×1[m]) / (fiber thread density [threads / m 2 ]×π×(d / 2) 2 [m 2 ]×1[m]×density of fiber structure [g / m 3 ]) = 4 / (d[m] × density of fiber structure [g / m 3 ])
[0024] When a woven fabric is used as the fiber structure, it is preferable to weave the fabric so that the sum of the cover factors (CF) in the warp and weft directions (total CF) is set in the range of 500 to 4000, more preferably in the range of 1000 to 3000, and even more preferably in the range of 1200 to 2000. When the total CF is set within the above range, there is a tendency that the interfiber distance required for supporting the antiviral compound (A) can be sufficiently maintained. The total CF can be calculated by the following formula:
[0025]
number
[0026] When a knitted fabric is used as the fiber structure, the course density is preferably 40 to 200 pieces / 2.54 cm, more preferably 50 to 150 pieces / 2.54 cm, and even more preferably 60 to 120 pieces / 2.54 cm. The wale density is preferably 30 to 180 pieces / 2.54 cm, more preferably 40 to 160 pieces / 2.54 cm, and even more preferably 50 to 140 pieces / 2.54 cm. The course density and wale density can be measured in accordance with JIS-L1096 8.6.2 Density of knitted fabrics. When measuring visually, the point on the structure diagram with the most knit loops in the wale direction (or course direction) is selected, and the number of knit loops is measured to determine the density.
[0027] <Antiviral Compound (A)> Next, the antiviral compound (A) used in the present invention is a quaternary ammonium halide having a molecular weight of 3,000 or less.
[0028] Examples of such quaternary ammonium halides include didecyldimethylammonium chloride (hereinafter sometimes abbreviated as "DDAC"), polyhexamethylene biguanidine chloride (hereinafter sometimes abbreviated as "PHMB"), tetramethylammonium iodide, trimethyldecylammonium bromide, didecyldimethylammonium bromide (hereinafter sometimes abbreviated as "DDAB"), dodecyldimethyl-2-phenoxyethylammonium bromide, lauryltrimethylammonium bromide, cetyltrimethylammonium bromide, trimethylammonium chloride, trimethyldodecylammonium chloride, trimethyltetradecylammonium chloride, trimethylcetylammonium chloride, trimethylcetylammonium bromide, trimethylcetylammonium iodide, trimethylstearylammonium chloride, trimethylstearylammonium bromide, trimethylstearylammonium iodide, cetylpyridinium ... bromide, trimethylstearylammonium iodide, trimethylstearylammonium bromide, trimethylstearylammonium bromide, trimethylstearylammonium iodide, trimethylstearylammonium bromide, trimethylstearylammonium bromide, trimethylstearylammonium iodide, trimethylstearylammonium bromide, trimethylstearylammonium bromide, trimethylstearylammonium iodide, trimethylste ammonium chloride, trimethylhexadecyl ammonium chloride, trimethyloctadecyl ammonium chloride, didecyl monomethyl hydroxyethyl ammonium bromide, alkyl dimethyl hydroxyethyl ammonium chloride, alkyl trimethyl ammonium bromide, dioctyl dimethyl ammonium chloride, dioctyl dimethyl ammonium bromide, octyl decyl dimethyl ammonium chloride, octyl decyl dimethyl ammonium bromide, methyl benzethonium chloride, alkyl dimethyl benzyl ammonium chloride (hereinafter sometimes abbreviated as "BAC"), alkyl pyridinium ammonium chloride, dialkyl methyl benzyl ammonium chloride, alkyl diamino ethyl glycine chloride, alkyl diamino ethyl glycine bromide, alkyl diamino ethyl glycine iodide, tetrabutyl ammonium chloride, tetrabutyl ammonium bromide, tetrabutyl ammonium iodide, and the like. In addition, polymers such as poly-oxyethylene(dimethylimino)ethylene(dimethylimino)ethylene dichloride (hereinafter sometimes abbreviated as "PDIEC"), poly[oxyethylene(dimethyliminio)trimethylene(dimethyliminio)ethylene dichloride], polydiallyldimethylammonium chloride, and N,N-didecyl-N-methyl-poly(oxyethyl)ammonium chloride can also be used so long as their molecular weight is 3000 or less.
[0029] Among these, when the anion species constituting the quaternary ammonium halide of the antiviral compound (A) is any one of iodide, bromide, and chloride, it can strongly adsorb to and denature the amino acid of the protein constituting the virus regardless of the type of the virus, so that it can exhibit more excellent antiviral properties, and it is more preferable that it is any one of bromide and chloride. In particular, DDAC, PHMB, DDAB, BAC, PDIEC, etc. are preferably used as the antiviral compound (A), and among them, DDAC and PHMB are more preferably used. These can be used alone or in combination of two or more kinds.
[0030] When the quaternary ammonium halide of the antiviral compound (A) is a salt of an anion and a cation, the antiviral compound (A) can be more firmly supported on the fiber structure, and the antiviral property can be maintained for a longer period.
[0031] The quaternary ammonium halide may be produced according to a known method, or may be a commercially available product. The quaternary ammonium halide may be used alone or in combination of two or more kinds.
[0032] The antiviral fiber structure of the present invention preferably contains the antiviral compound (A) in a ratio of 0.1 to 8 parts by weight, more preferably 0.1 to 4.4 parts by weight, even more preferably 0.1 to 1 part by weight, and even more preferably 0.2 to 0.8 parts by weight, relative to 100 parts by weight of the fiber structure. When the ratio of the antiviral compound (A) to the fiber structure is set within the above range, there is a tendency for the antiviral compound to exhibit better antiviral properties. However, if the content of the antiviral compound (A) is too high, this is not preferable because it may cause abnormalities (hardening, shrinkage, discoloration, etc.) in the antiviral fiber structure.
[0033] The ratio of the antiviral compound (A) to the fiber structure in the antiviral fiber structure can be determined, for example, by supporting a treatment liquid having a predetermined amount of the antiviral compound (A) on the fiber structure at a squeezing rate of 100%, thereby obtaining an antiviral fiber structure in which the predetermined amount of the antiviral compound (A) is supported on the fiber structure.
[0034] That is, the above-mentioned "wringing rate" generally serves as a guideline for how much of the treatment liquid to leave in the fiber structure, etc., when the fiber structure, etc., is dehydrated by squeezing it with a mangle or the like after impregnating the fiber structure, etc. with a treatment liquid in which the treatment agent is made into an aqueous solution or dispersion state, in the case of applying a specific treatment agent (e.g., a dye, etc.) to a fiber structure, yarn, etc., to perform fiber processing (dyeing processing, etc.). Note that by drying the dehydrated fiber structure, etc. (containing a certain amount of treatment liquid) to remove moisture, the treatment agent remains, adheres to, and is supported on the fiber structure, etc., and the desired treated and processed product is obtained. Such a wringing rate can be calculated by the following formula. Squeezing rate (%) = [(BA) / A] x 100 A: Initial (before treatment) fiber structure weight B: Fiber structure weight after dehydration
[0035] A "squeezing rate of 100%" means that after processing, (fibrous structure, etc. + processing liquid) is dehydrated so that an amount of processing liquid (e.g., 100 parts by weight) equal to the weight (e.g., 100 parts by weight) of the dried fibrous structure, etc. before processing is retained in the fibrous structure, etc. (in the above formula, B = 2A). If, for example, 5 parts by weight of the treatment liquid retained in the fiber structure etc. after the dehydration is a treatment agent (= treatment liquid concentration is 5% by weight), when the "fiber structure etc. after dehydration" containing this treatment liquid is dried to remove the moisture, a treated fiber structure is obtained in which 5 parts by weight of the treatment agent is supported on the fiber structure etc. (weight of the initial fiber structure etc.: 100 parts by weight).
[0036] In addition, when the antiviral compound (A) is supported on at least the surface of the antiviral fiber structure of the present invention, it tends to exhibit excellent antiviral properties even when it comes into contact with the target virus for a short period of time. The term "supported on at least the surface" does not mean that it is required to penetrate into the fibers of the target fiber structure, and for example, even if the fibers are made of a hydrophobic material, it is sufficient that the compound is supported on the surface. Of course, it may be capable of penetrating into the fibers.
[0037] The antiviral fiber structure of the present invention may contain a film-forming compound as appropriate. The film-forming compound is a compound having a bonding effect, and examples of the film-forming compound include melamine compounds, glyoxal compounds, urethane compounds, blocked isocyanate compounds, silicone compounds, acrylic resins, polyester resins, and acrylic resins containing silicone as organosiloxane. Among the above-mentioned coating-forming compounds, compounds such as melamine-based compounds and glyoxal-based compounds that cause a crosslinking reaction to form a chemical bond between the fiber structure and the antiviral compound (A) are preferred because they further improve the bonding strength of the antiviral compound (A). However, the coating-forming compound that can be used in the present invention is not necessarily limited to substances that cause chemical bonds, and even compounds that do not undergo crosslinking reactions can be used as long as they increase the affinity between the antiviral compound (A) and the fiber structure and support the antiviral compound (A) on the surface of the fiber structure. These can be used alone or in combination of two or more kinds.
[0038] When the coating compound is added to the treatment liquid having the antiviral compound (A) of the present invention, the content of the coating compound is not particularly limited. However, the concentration of the coating compound in the treatment liquid is preferably 0.01% by weight or more and 0.5% by weight or less, and more preferably 0.03% by weight or more and 0.3% by weight or less. In other words, the treatment liquid is preferably one that can adjust the coating compound to a wringing rate of 0.01% owf or more and 0.5% owf or less, assuming a wringing rate of 100%, for the target fiber structure, and more preferably one that can adjust the wringing rate to 0.03% owf or more and 0.3% owf or less.
[0039] In addition to the above, the antiviral fiber structure of the present invention may contain, if necessary, any known optional components such as fiber processing aids, deodorants, preservatives, fragrances, oily components, thickeners, moisturizers, pigments, pH adjusters, ceramides, sterols, antioxidants, singlet oxygen quenchers, ultraviolet absorbers, whitening agents, anti-inflammatory agents, antibacterial agents, other antiviral agents, etc., in order to improve the antiviral properties, prolong the effect, etc. These may be used alone or in combination of two or more kinds.
[0040] Examples of the fiber processing aid include antistatic agents, flame retardants, softeners, fixers, stain resistant agents, dye retardants, fluorescent brighteners, swelling agents, penetrating agents, emulsifiers, dispersants, sequestering agents, leveling agents, suspending agents, migration inhibitors, carriers, dye resists, wrinkle inhibitors, texture finishers, etc. Use of the fiber processing aids tends to prevent abnormalities such as discoloration, hardening, and shrinkage of the fiber structure, and loss of the antiviral properties of the antiviral compound (A), etc.
[0041] Specific examples of such fiber processing auxiliaries include alkali salt compounds such as anhydrous sodium carbonate, neutral salt compounds such as sodium sulfate (mirabilite), nonionic surfactants such as alkyl ether type, polycyclic phenyl ether type, sorbitan derivatives, and aliphatic polyether type, cationic surfactants such as quaternary ammonium salts (excluding quaternary ammonium halides used as the antiviral compound (A)), anionic surfactants such as sodium dialkyl succinate sulfonate and naphthalene sulfonate-formaldehyde condensates, and fluorescent whitening agents such as bis(triazinylamino)stilbene disulfonic acid derivatives, bisstyryl biphenyl derivatives, coumarin derivatives, and pyrazoline derivatives. These can be used alone or in combination of two or more.
[0042] In the case where the fiber structure used in the present invention is a nonwoven fabric, it is preferable to use at least one selected from the group consisting of antistatic agents, flame retardants, and softeners among the above-mentioned fiber processing auxiliaries. In particular, a cationic antistatic agent is preferable because it is possible to add a function without inhibiting the antiviral property.
[0043] <Method of manufacturing antiviral fiber structure> Such an antiviral fiber structure can be produced, for example, as follows: A treatment solution containing the antiviral compound (A) is prepared (treatment solution preparation step), and the fiber structure is brought into contact with the treatment solution (treatment solution contact step), thereby obtaining the antiviral fiber structure of the present invention.
[0044] (Processing solution preparation process) The treatment liquid containing the antiviral compound (A) is, for example, an aqueous solution in which the antiviral compound (A) is dissolved in water, but in some cases, a solution or dispersion in an organic solvent is used. The treatment liquid can contain the fiber processing auxiliary and optional components according to the type of the target fiber structure, the treatment conditions, etc.
[0045] Furthermore, in the above-mentioned treatment liquid, depending on the type of fiber processing aid and optional components used, the material of the fiber of the target fiber structure, etc., water-soluble organic solvents such as ethanol, n-propanol, ethylene glycol, etc. can be used together with or instead of water. In some cases, non-aqueous solvents can also be used. These can be used alone or in combination of two or more kinds.
[0046] (Processing liquid contact step) For example, a method (first method) in which the fiber structure is immersed in the treatment liquid can be mentioned, and another method (second method) in which the treatment liquid is applied to the fiber structure by spraying, coating, or the like can be mentioned.
[0047] In the first method, the content of the antiviral compound (A) in the treatment solution is preferably set to 0.005 to 20.0% owf (on weight of fiber, weight relative to the fiber structure, w / w), and more preferably 0.01 to 10.0% owf. The bath ratio (amount of solution relative to the target material, weight ratio) is preferably 1:5 to 1:30, and more preferably 1:5 to 1:20.
[0048] In the second method, when the treatment liquid is applied to a fiber structure by spraying, coating or the like under normal pressure, the ratio of the antiviral compound (A) to the treatment liquid used is preferably 0.005 to 20.0% ows (on weight of solution, concentration of the antiviral compound (A) in the treatment liquid, w / w), and more preferably 0.01 to 10.0% ows.
[0049] (Heat treatment process) The antiviral fiber structure of the present invention can be obtained in this manner. It is preferable that the antiviral fiber structure is further subjected to a heat treatment including a curing treatment at 40 to 230°C under normal pressure or pressure after the step of contacting the fiber structure with the treatment liquid.
[0050] The antiviral fiber structure obtained by the first method is preferably subjected to a heat treatment while immersed in the treatment solution. The treatment conditions, such as temperature, time, and pressure, are appropriately set according to the material and form of the fiber, but are usually set within the ranges of 40 to 230°C and 0.1 to 60 minutes, and the higher the temperature and pressure, the shorter the heat treatment time is set. Therefore, when treating a fiber structure made of fibers for which high temperature and long-term heating is not preferable, it is preferable to relax the heating conditions by applying pressure. When treating a fiber structure made of chemical fibers continuously, it is preferable to treat it at normal pressure from the viewpoint of equipment, and when treating it in a batch system, it is preferable to shorten the treatment time by applying pressure. There is no restriction on the pressure when pressing the fiber structure, and it may be within the range of pressure generated when heating in a closed system, for example.
[0051] The antiviral fiber structure obtained by the second method is preferably squeezed to a predetermined squeezing ratio using a mangle or centrifugation, and then heat-treated under normal pressure or pressure. The heat-treatment is preferably carried out at a treatment temperature of, for example, 40 to 230°C, and specifically, for example, drying at 100 to 130°C for 1 to 3 minutes (preliminary drying may not be carried out when the basis weight is small).
[0052] As described above, the antiviral fiber structures obtained by the first and second methods are preferably cured at 40 to 230°C, more preferably 80 to 130°C, after the heat treatment step. The time for the curing treatment is preferably about 30 seconds to 1 hour depending on the basis weight and physical properties of the fiber structure. If the temperature and time of the curing treatment are insufficient, the antiviral properties tend to be poor. On the other hand, if the temperature and time of the curing treatment exceed the above ranges, abnormalities (hardening, shrinkage, discoloration, etc.) of the fiber structure tend to occur.
[0053] In order to sufficiently fix the antiviral compound (A) to the fiber structure, it is preferable to carry out a curing treatment at a high temperature (80°C or higher). However, if the fiber is to be used for disposable purposes, it does not need to be used repeatedly and washing durability is not required. Therefore, the curing treatment may be carried out at a low temperature (less than 70°C), more preferably at 40 to 230°C, and even more preferably at 80 to 130°C.
[0054] The antiviral fiber structure thus obtained has the antiviral compound (A) supported on at least the surface of the fiber structure, and can exhibit antiviral properties against both enveloped and non-enveloped viruses. Moreover, it is highly safe for the human body and can be preferably used for clothing and interior applications. In addition, since a fiber structure having a specific basis weight is used, it is considered that the target virus is more likely to migrate inside the fiber structure, and the probability of contact with the antiviral compound (A) supported on the fiber structure is increased, and therefore the target virus can be inactivated in a short period of time. Furthermore, it can exhibit excellent antiviral properties against the new coronavirus in a short period of time.
[0055] <Anti-virus processed products> The antiviral fiber structure of the present invention can be used in a variety of processed products. Examples of such processed products include medical supplies (protective clothing, sterilization bags, etc.), hygiene products (dustbins, disposable gloves, disposable masks, etc.), cooking supplies (trays, etc.), bedding (curtains, sheets, towels, bedding material, bedding cotton, mats, carpets, pillowcases, etc.), clothing (coats, suits, sweaters, blouses, dress shirts, underwear, hats, masks, socks, gloves, etc.), uniforms (lab coats, work clothes, school uniforms, etc.), etc. Other than medical supplies, other examples include protective clothing, diapers, nursing sheets, shower curtains, car seats, seat covers, interior materials such as ceiling materials, tents, insect and bird netting, partition sheets, air conditioning filters, vacuum cleaner filters, masks, tablecloths, desk mats, aprons, wallpaper, wrapping paper, etc. In particular, because it is expected that the antiviral fiber structure can effectively exhibit antiviral properties against the new coronavirus simply by contacting the surface thereof, it is preferably used for medical supplies (protective clothing, sterilization bags, etc.), (dust boxes, disposable gloves, disposable masks, etc.), cooking utensils (trays, etc.), and protective clothing other than medical supplies, and is particularly preferably used as protective clothing (including medical supplies).
[0056] <Performance and evaluation of antiviral fiber structures> The antiviral fiber structure of the present invention has antiviral properties, and is particularly effective against enveloped viruses. In addition, since the antiviral properties are observed even after short-term contact (e.g., 5 to 10 minutes), the antiviral fiber structure can be preferably used in medical supplies against viruses that require more careful handling.
[0057] More specifically, the types of viruses against which the antiviral fiber structure of the present invention is effective include enveloped viruses such as poxviruses, orthomyxoviruses (representative examples are human influenza virus and avian influenza virus), coronaviruses, paramyxoviruses, arenaviruses, rhabdoviruses, retroviruses, bunyaviruses, herpesviruses, togaviruses, papovaviruses, porvoviruses, and filoviruses, and are particularly effective against human influenza viruses, avian influenza viruses, and coronaviruses, and are also extremely effective against the novel coronavirus (SARS-CoV-2).Other examples include non-enveloped viruses such as adenoviruses, polioviruses, noroviruses, and rotaviruses.
[0058] Next, a test method for evaluating the antiviral activity of the present invention will be described.
[0059] <Test methods for evaluating antiviral properties> In the present invention, the antiviral properties are evaluated by judging the effectiveness based on the antiviral activity value determined by the antiviral measurement method described below. Note that an antiviral activity value of 5 means that the viral infectivity titer (the number of viral particles capable of infecting cells) has been reduced to 1 / 100,000 (the virus has been inactivated).
[0060] (Antiviral Assay Method) The target virus is the novel coronavirus (enveloped type). The novel coronavirus used is SARS-CoV-2 (JPN / TY / WK521). The fiber structure to be measured is contacted with a liquid containing the virus (hereinafter referred to as "virus liquid") for 10 minutes at room temperature, and then the virus liquid is post-cultured in VeroE6 / TMPRSS2 cells. The increase or decrease in virus (infectivity titer) in the cultured cells is calculated, and the logarithmic difference with the blank (untreated material) is calculated to determine the antiviral activity value. EXAMPLES
[0061] Next, examples of the present invention will be described together with comparative examples, but the present invention is not limited to the following examples.
[0062] [Examples 1 to 11, Comparative Examples 1 to 3] First, an antiviral fiber structure of the present invention was produced by the procedure described below using the antiviral compound (A) and a fiber structure as shown in Table 1. The values of the antiviral compound (A) in Table 1 are shown in parts by weight relative to 100 parts by weight of the fiber structure. The abbreviations of the antiviral compounds (A) used and details of the fiber structures are shown below.
[0063] Antiviral compounds (A) DDAC: Didecyldimethylammonium chloride (molecular weight: 362) PHMB: Polyhexamethylene biguanidine chloride (molecular weight: 2000) BAC: alkyldimethylbenzylammonium chloride (molecular weight: 354) PDIEC: Polyoxyethylene (dimethylimino) ethylene (dimethylethyleneimino) ethylene dichloride (molecular weight: 4000 or more)
[0064] Fiber structure Nonwoven fabric 1: 100% polyethylene terephthalate (PET), single yarn fineness 3dtex, basis weight 50g / m 2 . Nonwoven fabric 2: 100% polypropylene (PP), single yarn fineness 3dtex, basis weight 40g / m 2 . Nonwoven fabric 3: PP / polyethylene (PE) blend, single yarn fineness 3dtex, basis weight 20g / m 2 . Nonwoven fabric 4: PET / PE blend, single yarn fineness 3dtex, basis weight 32g / m 2 . Nonwoven fabric 5: PET / rayon blend, single yarn fineness 3dtex, basis weight 50g / m 2 . Fabric 1: 65% PET / 35% cotton blend (T / C), single yarn size 45dtex, basis weight 75g / m2 , total CF1644. Fabric 2: 65% PET / 35% cotton blend (T / C), single yarn size 157dtex, basis weight 200g / m 2 , total CF2683. Fabric 3: 100% cotton, single yarn size 197dtex, weight 250g / m 2 , total CF3000.
[0065] Then, a treatment solution was prepared by adding each antiviral compound (A) in the ratio shown in Table 1. Each fiber structure was immersed in the treatment solution for 2 seconds, and then 100% squeezed with a mangle. The nonwoven fabrics (1 to 5) were cured at 130°C for 1 minute. The woven fabrics (1 and 2) were cured at 180°C for 1.5 minutes. The woven fabric 3 was cured at 100°C for 1.5 minutes. The pressure during processing was normal pressure (neither pressurized nor reduced pressure) at all stages.
[0066] The antiviral activity of each of the antiviral fiber structures thus obtained was measured by the above-mentioned antiviral measurement method, and the antiviral properties were evaluated based on the following indices. The results are shown in Table 1 below. ×: Antiviral activity value less than 2.0. △: Antiviral activity value is 2.0 or more and less than 3.0. 〇: Antiviral activity value is 3.0 or more and less than 5.0. ◎: Antiviral activity value is 5.0 or higher.
[0067] [Table 1]
[0068] From the results in Table 1 above, it can be seen that all of the example products of the present invention, Examples 1 to 11, exhibit excellent antiviral properties. Moreover, it was found that the example products of the present invention exhibit sufficient effects even with short-term contact, and are particularly effective against the novel coronavirus. On the other hand, as a fiber structure, the basis weight is 120g / m 2In Comparative Examples 1 and 2, in which compounds having a molecular weight exceeding 3,000 were used, antiviral properties could not be exhibited. In Comparative Example 3, in which a quaternary ammonium halide was used as the antiviral compound (A) but the molecular weight exceeded 3,000, antiviral properties could not be exhibited. [Industrial Applicability]
[0069] The present invention reliably exhibits antiviral properties even after short-term contact, and can be used as a highly safe antiviral fiber structure.
Claims
1. An antiviral fiber structure having an antiviral compound (A) supported on a fiber structure, the antiviral compound (A) being a quaternary ammonium halide having a molecular weight of 3000 or less, and the fiber structure having a basis weight of 110 g / m 2 Any of the following nonwoven, woven, or knitted fabrics: When the fiber structure is a nonwoven fabric, the fiber single filament fineness is in the range of 0.5 to 10 dtex, When the fiber structure is a woven or knitted fabric, the fiber has a single filament fineness in the range of 30 to 400 dtex; An antiviral fiber structure (excluding those containing porous particles), characterized in that the antiviral compound (A) is contained in an amount of 0.1 to 8 parts by weight per 100 parts by weight of the fiber structure.
2. 2. The antiviral fiber structure according to claim 1, wherein the antiviral compound (A) is supported on at least the surface of the fiber structure.
3. 3. The antiviral fiber structure according to claim 1, wherein the quaternary ammonium halide of the antiviral compound (A) is a salt of an anion and a cation.
4. The antiviral fiber structure according to any one of claims 1 to 3, wherein the anion species constituting the quaternary ammonium halide of the antiviral compound (A) is at least one selected from the group consisting of iodide, bromide and chloride.
5. The antiviral fiber structure according to any one of claims 1 to 4, wherein the target virus is at least one selected from the group consisting of influenza virus, norovirus, and coronavirus.
6. The antiviral fiber structure according to any one of claims 1 to 5, wherein the fiber structure comprises at least one fiber selected from the group consisting of polyester-based resins, polyamide-based resins, acrylic-based resins, polyurethane-based resins, polyolefin-based resins, cellulose-based resins, acetate resins, cotton, hemp, wool, and silk.
7. The antiviral fiber structure according to any one of claims 1 to 6, wherein the fiber structure is a nonwoven fabric.
8. The antiviral fiber structure according to any one of claims 1 to 7, further comprising a fiber processing aid.
9. 9. The antiviral fiber structure according to claim 8, wherein the fiber processing aid is at least one selected from the group consisting of antistatic agents, flame retardants and softening agents.
10. A method for producing an antiviral fiber structure according to any one of claims 1 to 9, comprising the steps of: preparing a treatment liquid containing the antiviral compound (A); contacting the fiber structure with the treatment liquid; and drying the fiber structure contacted with the treatment liquid.
11. The method for producing an antiviral fiber structure according to claim 10, further comprising a heat treatment step including a treatment at 40 to 230° C. under normal pressure or pressure, after the step of contacting the fiber structure with the treatment liquid.
12. An antiviral processed product, which is obtained by processing the antiviral fiber structure according to any one of claims 1 to 9.
13. The antiviral treated product according to claim 12, which is at least one selected from the group consisting of medical supplies, sanitary supplies and cooking supplies.
14. The antiviral treated product according to claim 12 or 13, which is a protective garment.
15. An antiviral fiber structure having an antiviral compound (A) and a fiber structure, from which moisture has been removed, wherein the antiviral compound (A) is a quaternary ammonium halide having a molecular weight of 3000 or less, and the fiber structure has a basis weight of 110 g / m 2 Any of the following nonwoven, woven, or knitted fabrics: When the fiber structure is a nonwoven fabric, the fiber single filament fineness is in the range of 0.5 to 10 dtex, When the fiber structure is a woven or knitted fabric, the antiviral fiber structure is characterized in that the single fiber fineness is in the range of 30 to 400 dtex (excluding those containing porous particles).
16. An antiviral fiber structure having an antiviral compound (A) and a fiber structure, wherein the antiviral compound (A) is a quaternary ammonium halide having a molecular weight of 3000 or less, and the fiber structure has a basis weight of 110 g / m 2 Any of the following nonwoven, woven, or knitted fabrics: When the fiber structure is a nonwoven fabric, the fiber single filament fineness is in the range of 0.5 to 10 dtex, When the fiber structure is a woven or knitted fabric, the fiber has a single filament fineness in the range of 30 to 400 dtex; An antiviral fiber structure (excluding those containing porous particles) that is used for one selected from the group consisting of protective clothing, sterilization bags, dustbins, disposable gloves, disposable masks, cooking utensils, bedding, clothing, uniforms, diapers, nursing sheets, shower curtains, car seats, seat covers, interior materials, tents, insect and bird repellent nets, partition sheets, air conditioning filters, vacuum cleaner filters, masks, tablecloths, desk mats, aprons, wallpaper, and wrapping paper.
17. An antiviral fiber structure having an antiviral compound (A) and a fiber structure, wherein the antiviral compound (A) is a quaternary ammonium halide having a molecular weight of 3000 or less, and the fiber structure has a basis weight of 110 g / m 2 Any of the following nonwoven, woven, or knitted fabrics: When the fiber structure is a nonwoven fabric, the fiber single filament fineness is in the range of 0.5 to 10 dtex, When the fiber structure is a woven or knitted fabric, the antiviral fiber structure (excluding wet wipers, cleaning sheets, and those containing porous particles) is characterized in that the single fiber fineness is in the range of 30 to 400 dtex.
Citation Information
Patent Citations
Antibiosis solution used for dressing, antibiosis dressing and preparation method for antibiosis dressing
CN104248776A
Method for producing antimicrobial fiber product, and antimicrobial composition for fiber
JP2003105674A
Sterilizing disinfectant-containing wet wiper
JP2009256338A
Protective article and method for manufacturing the same
JP2010131971A
Composition for virus inactivation
JP2013014551A
